donepezil has been researched along with sb 216763 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, T; Chen, Y; Feng, F; Jiang, X; Li, Q; Liu, C; Liu, W; Lyu, W; Sun, H; Wang, S; Wang, Y; Xing, C | 1 |
| Feng, F; Jiang, X; Li, Y; Lin, T; Liu, C; Liu, W; Lyu, W; Sun, H; Xie, H; Xu, J; Zou, M | 1 |
2 other study(ies) available for donepezil and sb 216763
| Article | Year |
|---|---|
Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Glycogen Synthase Kinase 3 beta; Humans; Molecular Structure; Neuroprotective Agents; Protein Kinase Inhibitors; Pyridines; Structure-Activity Relationship; Thiazoles; Tumor Cells, Cultured | 2021 |
Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in th
Topics: Acetylcholine; Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Blood-Brain Barrier; Brain; Cholinesterase Inhibitors; Drug Design; Glycogen Synthase Kinase 3 beta; Humans; Intestines; Mice; Mice, Inbred ICR; Molecular Dynamics Simulation; Neuroprotective Agents; Niacinamide; Protein Kinase Inhibitors; Structure-Activity Relationship; Up-Regulation | 2021 |